Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
作者： L. M. Ellis , D. J. Hicklin
DOI: 10.1158/1078-0432.CCR-09-1070
关键词: Predictive biomarker 、 Pharmacology 、 Bioinformatics 、 Patient survival 、 Targeted therapy 、 Acquired resistance 、 Cancer 、 Novel agents 、 Intrinsic resistance 、 Molecular oncology 、 Medicine
摘要: The advent of targeted therapy for treatment of human cancers has added significantly to our armamentarium as we strive to prolong patient survival while minimizing toxicity. In cancers …
aacrjournals.org
scilit.net参考文章(43)
John M.L. Ebos, Christina R. Lee, William Cruz-Munoz, Georg A. Bjarnason, James G. Christensen, Robert S. Kerbel, Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Cancer Cell. ,vol. 15, pp. 232- 239 ,(2009) , 10.1016/J.CCR.2009.01.021
Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers, Douglas Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell. ,vol. 8, pp. 299- 309 ,(2005) , 10.1016/J.CCR.2005.09.005
Lee M. Ellis, David A. Reardon, Cancer: The nuances of therapy. Nature. ,vol. 458, pp. 290- 292 ,(2009) , 10.1038/458290A
Lucia Regales, Marissa N. Balak, Yixuan Gong, Katerina Politi, Ayana Sawai, Carl Le, Jason A. Koutcher, David B. Solit, Neal Rosen, Maureen F. Zakowski, William Pao, Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLOS ONE. ,vol. 2, ,(2007) , 10.1371/JOURNAL.PONE.0000810
P. S. Hammerman, P. A. Janne, B. E. Johnson, Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 15, pp. 7502- 7509 ,(2009) , 10.1158/1078-0432.CCR-09-0189
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, S. Kesari, P. Y. Wen, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. ,vol. 72, pp. 779- 787 ,(2008) , 10.1212/01.WNL.0000304121.57857.38
Lee M. Ellis, Daniel J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity Nature Reviews Cancer. ,vol. 8, pp. 579- 591 ,(2008) , 10.1038/NRC2403
L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, N. Silliman, S. Szabo, Z. Dezso, V. Ustyanksky, T. Nikolskaya, Y. Nikolsky, R. Karchin, P. A. Wilson, J. S. Kaminker, Z. Zhang, R. Croshaw, J. Willis, D. Dawson, M. Shipitsin, J. K. V. Willson, S. Sukumar, K. Polyak, B. H. Park, C. L. Pethiyagoda, P. V. K. Pant, D. G. Ballinger, A. B. Sparks, J. Hartigan, D. R. Smith, E. Suh, N. Papadopoulos, P. Buckhaults, S. D. Markowitz, G. Parmigiani, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, Genomic landscapes of human breast and colorectal cancers Science. ,vol. 318, pp. 1108- 1113 ,(2008) , 10.1126/SCIENCE.1145720
Gabriele Bergers, Douglas Hanahan, Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer. ,vol. 8, pp. 592- 603 ,(2008) , 10.1038/NRC2442